Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs

(2018) Enrico Munari et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer

(2018) H Wang et al.   ANNALS OF ONCOLOGY

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations

(2018) Bryce Noll et al.   CANCER CYTOPATHOLOGY

PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections

(2018) Enrico Munari et al.   Journal of Thoracic Oncology

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

(2018) Shona Hendry et al.   Journal of Thoracic Oncology

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

(2017) Silvia Pesce et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability

(2017) Hans Brunnström et al.   MODERN PATHOLOGY

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability

(2017) Enrico Munari et al.   Oncotarget

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx

(2017) Birgit G. Skov et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

(2015) Yuankai Shi et al.   PLoS One

Principles of Analytic Validation of Immunohistochemical Assays: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center

(2014) Patrick L. Fitzgibbons et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer

(2013) J. R. Brahmer et al.   Cancer Immunology Research

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE